Status:
NOT_YET_RECRUITING
Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study
Lead Sponsor:
Rahma Esam Salama Esawi
Collaborating Sponsors:
Assiut University
Conditions:
Breast Cancer Stage I
Breast Cancer Stage II
Eligibility:
FEMALE
18-80 years
Brief Summary
Global cancer statistics by world region for the year 2022 estimated breast cancer the 2nd cause of new cancer cases (11.6%). (1) Approximately 80% of all breast cancers (BCs) are currently categorize...
Detailed Description
a prospective observational cohort study on the role of TREM-1 as a novel immune biomarker in HER-2 breast cancer it's a molecular and clinical study. our aim is to assess prognostic significance of T...
Eligibility Criteria
Inclusion
- female patient aged \< 18 yrs. old
- histological proven breast cancer
- HER-2 negative (hormonal positive or triple negative)
- planned to receive neo-adjuvant therapy
- complete clinical, radiological and therapeutic data
Exclusion
- metastatic breast cancer
- HER-2 positive
- incomplete clinical, radiological or therapeutic data
Key Trial Info
Start Date :
September 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06950671
Start Date
September 15 2025
End Date
September 1 2029
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospitals
Asyut, Egypt, Egypt, 71631